ClinicalTrials.gg
CompletedNCT01000480Updated Apr 2, 2014Results posted

A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer

A Phase 2 interventional study of Pemetrexed and Cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 21 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-02.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
96th of 223
90 · median 64
Started
2009
with 20 others
Phase 2
128 of 227
12 open now
Registered
95th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 96th largest by enrollment of the 223 interventional ones that give a count, is one of 21 that started in 2009, is one of 128 in phase 2, and was the 95th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This trial investigates pemetrexed and cisplatin followed by pemetrexed and cisplatin in combination with radiotherapy in participants with locally advanced, non-small cell lung cancer (NSCLC). The purpose of the study is to assess the antitumor activity as measured by progression free survival 1 year after start of treatment with study drug.

Read the detailed description

The participants will receive 2 cycles of pemetrexed and cisplatin. If the participants achieve complete response, partial response or stable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, have ≤35% of the total calculated lung volume receive more than 20 Gy (V20) according to the 3-dimensional (3-D) radiotherapy planning Dose Volume Histograms, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, have no residual neurological toxicity > Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), they will receive 2 additional cycles of pemetrexed and cisplatin, combined with radiotherapy. The combination of radiotherapy will begin 22 to 36 days after completion of the second infusion of induction therapy with pemetrexed-cisplatin.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis of unresectable nonsquamous Stage IIIA or Stage IIIB (without malignant pleural/pericardial effusions) NSCLC.
  • Have an performance status of 0 or 1.
  • Previous radiation therapy should have been limited and must not have included thoracic radiation, whole pelvis radiation, or radiation to >25% of the participant's bone marrow, participants must have recovered from the toxic effects of radiation treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry.
  • Have at least 1 unidimensionally meeting guidelines, version 1.0.
  • Estimated of at least 12 weeks.
  • Participant compliance and geographic proximity that allow adequate follow-up.
  • Adequate bone marrow reserve, hepatic-, renal- and pulmonary function.
  • Participants must sign an Document.
  • Participants must have a total lung V20 less than or equal to 35%.
  • For women: Must be surgically sterile, , or compliant with a medically approved regimen, during and for 6 months after the treatment period; must have a negative serum pregnancy test within 7 days before study enrollment and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.
  • Have not received prior systemic anticancer therapy for NSCLC.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within the last 30 days of enrollment with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Have previously completed or withdrawn from this study or any other study investigating pemetrexed.
  • Have a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the protocol.
  • Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the Class III or IV.
  • Have had a prior other than NSCLC, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Participants with a history of low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.
  • Are receiving concurrent administration of any other antitumor therapy.
  • Have had weight loss of more than 10% over the previous 3 months before study entry.
  • Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose less than or equal to 1.3 grams per day, for at least 2 days before (5 days for long-acting agents), the day of, and for at least 2 days after administration of pemetrexed.
  • Are unable or unwilling to take folic acid or vitamin B12 supplementation.
  • Are unable or unwilling to take .
  • Have received a recent yellow fever vaccination (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination.
  • Have known to pemetrexed, cisplatin, or any of the in these medicinal products.
  • Have evidence of clinical hearing loss.
  • Have third-space fluid collections, that cannot be controlled by drainage or other procedures prior to study entry.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.

    Drug: Pemetrexed · Drug: Cisplatin · Radiation: Thoracic Radiotherapy

Interventions

  • 500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.

    Also known as: Alimta, LY231514

  • 75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.

  • RadiationThoracic Radiotherapy

    Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.

06

What researchers measure

Primary outcomes

  1. 1 Year Progression Free Survival

    Progression free survival (PFS) was defined as the time from study enrollment to the first observation of progressive disease (PD) or death from any cause. For participants not known to have died as of the data cut-off date and who did not have objective PD, PFS was censored at the date of the last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from the study drug) prior to objectively determined PD or death, PFS was censored at the date of the last objective progression-free disease assessment prior to start of postdiscontinuation chemotherapy. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant.

    Time frame: Date of first dose to date of objectively determined PD or death [every cycle up to 4 cycles and then every 3 months up to 1 year (1 cycle=21 days)]

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was the duration from enrollment to death due to any cause. Participants who were alive were censored at the last contact.

    Time frame: Date of first dose to date of death (up to 35.4 months)

  2. Number of Participants With an Objective Tumor Response

    Participants with confirmed complete response (CR), confirmed partial response (PR), stable disease (SD), or progressive disease (PD) according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria, as well as participants with a not evaluable/tumor response unknown. CR: disappearance of all tumor lesions. PR: either a) at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as a reference baseline sum LDs, or b) complete disappearance of target lesions, with persistence (not worsening) of 1 or more nontarget lesions. In either case, no new lesions appeared. SD: small changes that did not meet above criteria. PD: at least a 20% increase in sum of LD of target lesions taking as reference smallest sum LD recorded since treatment started or appearance of 1 or more new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response.

    Time frame: Date of first dose through end of follow-up [up to 30 weeks (1 cycle=21 days)]

07

Results

Posted Jan 1, 2014

Participant flow

Induction Phase
Participant flow — Induction Phase
MilestonePemetrexed, Cisplatin, and Thoracic Radiotherapy
Started90
Received at least 1 dose of either drug90
Death (any cause) or disease progression8
Completed83
Not completed7
Withdrew: Adverse event2
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Entry criteria not met3
Concurrent Therapy Phase
Participant flow — Concurrent Therapy Phase
MilestonePemetrexed, Cisplatin, and Thoracic Radiotherapy
Started75
Death (any cause) or disease progression1
Completed65
Not completed10
Withdrew: Adverse event4
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1
Follow-Up Period
Participant flow — Follow-Up Period
MilestonePemetrexed, Cisplatin, and Thoracic Radiotherapy
Started88
Completed88
Not completed0

Outcome measures

Primary1 Year Progression Free Survival

Progression free survival (PFS) was defined as the time from study enrollment to the first observation of progressive disease (PD) or death from any cause. For participants not known to have died as of the data cut-off date and who did not have objective PD, PFS was censored at the date of the last objective progression-free disease assessment. For participants who received subsequent systemic anticancer therapy (after discontinuation from the study drug) prior to objectively determined PD or death, PFS was censored at the date of the last objective progression-free disease assessment prior to start of postdiscontinuation chemotherapy. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant.

Time frame:
Date of first dose to date of objectively determined PD or death [every cycle up to 4 cycles and then every 3 months up to 1 year (1 cycle=21 days)]
Reported as:
Number · percentage of participants
1 Year Progression Free Survival
percentage of participantsPemetrexed, Cisplatin, and Thoracic Radiotherapy
1 Year Progression Free Survival53.7 (44.8 to 62.5)
Statistical analysis
  • Pemetrexed, Cisplatin, and Thoracic Radiotherapy · maximum likelihood estimate · p = 0.0645 (P-value for H0 which compared the investigational regimen to historical data.)
SecondaryOverall Survival

Overall survival (OS) was the duration from enrollment to death due to any cause. Participants who were alive were censored at the last contact.

Time frame:
Date of first dose to date of death (up to 35.4 months)
Reported as:
Median · months
Overall Survival
monthsPemetrexed, Cisplatin, and Thoracic Radiotherapy
Overall Survival26.2 (16.7 to NA)
SecondaryNumber of Participants With an Objective Tumor Response

Participants with confirmed complete response (CR), confirmed partial response (PR), stable disease (SD), or progressive disease (PD) according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria, as well as participants with a not evaluable/tumor response unknown. CR: disappearance of all tumor lesions. PR: either a) at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as a reference baseline sum LDs, or b) complete disappearance of target lesions, with persistence (not worsening) of 1 or more nontarget lesions. In either case, no new lesions appeared. SD: small changes that did not meet above criteria. PD: at least a 20% increase in sum of LD of target lesions taking as reference smallest sum LD recorded since treatment started or appearance of 1 or more new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response.

Time frame:
Date of first dose through end of follow-up [up to 30 weeks (1 cycle=21 days)]
Reported as:
Number · participants
Number of Participants With an Objective Tumor Response
participantsPemetrexed, Cisplatin, and Thoracic Radiotherapy
Complete Response9
Partial Response45
Stable Disease16
Disease Progression12
Not evaluable/Response unknown8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed, Cisplatin, and Thoracic Radiotherapy—23/90 (25.6%)85/90 (94.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPemetrexed, Cisplatin, and Thoracic Radiotherapy
Radiation oesophagitisInjury, poisoning and procedural complications8/90
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/90
General physical health deteriorationGeneral disorders2/90
DehydrationMetabolism and nutrition disorders2/90
LeukopeniaBlood and lymphatic system disorders1/90
HypoacusisEar and labyrinth disorders1/90
ConstipationGastrointestinal disorders1/90
EnteritisGastrointestinal disorders1/90
Gastritis erosiveGastrointestinal disorders1/90
NauseaGastrointestinal disorders1/90
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPemetrexed, Cisplatin, and Thoracic Radiotherapy
NauseaGastrointestinal disorders43/90
DysphagiaGastrointestinal disorders27/90
OesophagitisGastrointestinal disorders23/90
ConstipationGastrointestinal disorders22/90
AstheniaGeneral disorders18/90
NeutropeniaBlood and lymphatic system disorders17/90
FatigueGeneral disorders14/90
CoughRespiratory, thoracic and mediastinal disorders14/90
DyspnoeaRespiratory, thoracic and mediastinal disorders13/90
LeukopeniaBlood and lymphatic system disorders12/90

Baseline characteristics

Intent-to-treat population: participants who received at least 1 dose of study drug (pemetrexed or cisplatin).

Age, Continuous
Age, Continuous(years)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
Mean61.7 ± 8.15
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
Female39
Male51
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
White90
Region of Enrollment
Region of Enrollment(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
France9
Spain17
Germany42
Italy22
Stage of Disease
Stage of Disease(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
Stage IIIA32
Stage IIIB56
Stage IV2
Eastern Cooperative Oncology Group (ECOG) performance status (PS)
Eastern Cooperative Oncology Group (ECOG) performance status (PS)(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
ECOG PS=059
ECOG PS=131
ECOG PS=20
Initial pathological diagnosis
Initial pathological diagnosis(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
Adenocarcinoma (lung)81
Carcinoma (large cell, lung)7
Carcinoma (non-small cell, lung, NOS)1
Carcinoma (non-small cell, poorly differentiated)1
Current Tobacco Use
Current Tobacco Use(participants)Pemetrexed, Cisplatin, and Thoracic Radiotherapy
Never used tobacco7
Former user of tobacco55
Current use of tobacco28
08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Le Mans, 72000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34070, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75015, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31300, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 14165, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hemer, 58675, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Köln, 51109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lübeck, 23538, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nürnberg, 90419, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avellino, 50019, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50139, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monza, 20900, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orbassano, 10043, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Perugia, 06156, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sabadell, 08208, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46010, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jan 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2009
First posted
Oct 23, 2009
Start
Oct 2009
Primary completionActual
Jan 2013
CompletionActual
Jul 2013
Results first posted
Jan 1, 2014
Last update
Apr 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01000480
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Oct 2009
Primary completion
Jan 2013
Completion
Jul 2013
Results posted
Jan 1, 2014
Last update
Apr 2, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT- 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion